Remix Therapeutics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of REM-422 in Patients With AML or Higher Risk MDS (NCT06297941) | Remix Therapeutics | 2024-04-26 |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma (NCT06118086) | Remix Therapeutics | 2023-12-20 |
Track Remix Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.